News
11 June 2021
Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner
Cambridge Cognition Holdings is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.
Read on
26 April 2021
Cognition and COVID-19: CANTAB Research Grant - Results
The results of the 2021 CANTAB Research Grant are in! This year's award was focussed on the connection between cognition and COVID-19.
Read on
8 April 2021
Cambridge Cognition provides cognitive assessments in an at-home clinical trial
Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial. The contract is worth approximately £0.5 million.
Read on
30 March 2021
Cambridge Cognition wins cognitive assessment contract for a schizophrenia trial
Cambridge Cognition has won a £1.3 million contract as the cognitive assessment partner for a schizophrenia trial.
Read on
21 December 2020
Cambridge Cognition provides digital assessments of mood and cognition for a depression trial
Cambridge Cognition has won a new contract with a major pharmaceutical client to provide digital assessments of mood and cognition for a depression trial. The contract is worth over £700,000 with most of the revenue expected to be recognised in 2021.
Read on
7 October 2020
Cambridge Cognition wins new digital health contract
Cambridge Cognition has won a new contract providing cognitive tests and electronic clinical outcome assessments for an Alzheimer’s trial. The total Contract is worth approximately £750,000 over two years, with a considerable proportion of the revenue for the Company expected to be received in 2021.
Read on
1 September 2020
Cambridge Cognition secures three late phase schizophrenia trials
Cambridge Cognition is pleased to announce that it has won a £2m contract as the cognitive assessment partner for three late phase clinical trials for a pharmaceutical company's lead drug candidate for patients with schizophrenia. It is one of the largest single contracts secured by the Company and the revenue from the contract should be booked over the next four years with the majority recognised in 2021.
